Last reviewed · How we verify
Zoledronic acid in combination with therapy
At a glance
| Generic name | Zoledronic acid in combination with therapy |
|---|---|
| Also known as | Zometa, Zomera, Aclasta, Reclast |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA (PHASE4)
- Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (PHASE1)
- Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites (PHASE1, PHASE2)
- Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (PHASE2)
- Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer (NA)
- ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers (PHASE1)
- MAGnesium Effect With ANtiosteoporotic Drugs (PHASE2)
- Trochanteric Femur Fracture Operated With Dynamic Hip Screw System (DHS) Augmented With a Biphasic Apatite Sulphate Combined With Systemic or Local Bisphosphonate (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |